Treating neural disease with tyrosine kinase inhibitors
US-2015087653-A1 · Mar 26, 2015 · US
Increasing parkin activity by administering a deubiquitinating enzyme inhibitor
US9393244B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9393244-B2 |
| Application number | US-201414212750-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 14, 2014 |
| Priority date | Mar 15, 2013 |
| Publication date | Jul 19, 2016 |
| Grant date | Jul 19, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are methods of promoting parkin activity in a subject, comprising: selecting a subject with a disorder associated with decreased Parkin activity; and administering to the subject an effective amount of a composition that increases parkin activity, wherein the composition is an inhibitor of a deubiquitinating enzyme.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of promoting parkin activity in a subject that has a neurodegenerative disease of the central nervous system, a myodegenerative disease or a prion disease, comprising: a) selecting a subject with a disorder associated with decreased parkin activity, wherein the disorder is a neurodegenerative disease of the central nervous system, a myodegenerative disease or a prion disease, wherein the neurodegenerative disease is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, and Mild Cognitive Impairment, an α-Synucleinopathy and a Tauopathy; and b) administering to the subject an effective amount of a composition that increases parkin activity, wherein the composition is an inhibitor of a deubiquitinating enzyme. 2. The method of claim 1 , wherein the deubiquitinating enzyme is USP-10 or USP-13. 3. The method of claim 1 , wherein the composition increases parkin activity by promoting the interaction between parkin and beclin-1. 4. The method of claim 1 , wherein the composition inhibits deubiquitination of parkin. 5. A method of treating a neurodegenerative disease, a myodegenerative disease or prion disease in a subject, comprising: a) selecting a subject with a neurodegenerative disease of the central nervous system, a myodegenerative disease, or a prion disease, wherein the neurodegenerative disease is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, and Mild Cognitive Impairment, an α-Synucleinopathy and a Tauopathy; and b) administering to the subject an effective amount of a composition that increases parkin activity, wherein the composition is an inhibitor of a deubiquitinating enzyme. 6. The method of claim 5 , wherein the deubiquitinating enzyme is USP-10 or USP-13. 7. The method of claim 5 , wherein the composition promotes the interaction between parkin and beclin-1. 8. The method of claim 5 , wherein the composition inhibits deubiquitination of parkin.
Assignees
Inventors
Classifications
- A61K31/496Primary
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
not condensed and containing further heterocyclic rings · CPC title
- A61K31/517Primary
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9393244B2 cover?
- Provided herein are methods of promoting parkin activity in a subject, comprising: selecting a subject with a disorder associated with decreased Parkin activity; and administering to the subject an effective amount of a composition that increases parkin activity, wherein the composition is an inhibitor of a deubiquitinating enzyme.
- Who is the assignee on this patent?
- Univ Georgetown
- What technology area does this patent fall under?
- Primary CPC classification A61K31/496. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).